|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Division of Respiratory Medicine, Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada.
Correspondence to: Donald W. Cockcroft, MD, FCCP, Division of Respiratory Medicine, Royal University Hospital, Ellis Hall, Fifth Floor, Saskatoon, SK, S7N 0W8 Canada; e-mail: cockcroft{at}sask.usask.ca
| Abstract |
|---|
|
|
|---|
Objective: To compare the 2-min tidal-breathing and the five-breath dosimeter methacholine challenges.
Setting: Tertiary care university-based bronchoprovocation laboratory.
Patients: Forty subjects with currently symptomatic asthma.
Interventions: The two methacholine tests were done in random order on separate days at the same time of day at 1- to 7-day intervals.
Results: The dosimeter provocation concentration of methacholine causing a 20% fall in FEV1 (PC20) was almost twice that of the tidal-breathing PC20: 2.4 mg/mL vs 1.3 mg/mL (paired t test, p < 0.00005). The difference was greater in those with mild airway hyperresponsiveness (AHR) [PC20 > 1.0 mg/mL; 3.2-fold] compared to those with moderate AHR (PC20 < 1.0 mg/mL; 1.6-fold) [p = 0.04]. Three subjects with mild asthma and mild AHR (tidal-breathing PC20, 1.9 to 4.3 mg/mL) had a nonmeasurable PC20 (> 32 mg/mL) with the dosimeter.
Conclusions: The tidal-breathing method, which exposes the subject to twice as much aerosol at each concentration, produced approximately twice the response. The total lung capacity maneuvers with breathhold during the dosimeter method may inhibit the response in some patients with asthma.
Key Words: airway responsiveness bronchoprovocation methacholine methods
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
65% predicted and a tidal-breathing provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) < 16 mg/mL. The study was approved by the University of Saskatchewan Ethics Committee, and signed informed consent was obtained.
Study Design
Subjects (n = 40) attended the laboratory on 2 days at the same time of day within 1 week. Inhaled albuterol (n = 39) or terbutaline (n = 1) was withheld for 6 h, and long-acting ß2-agonists (n = 3) for 36 h and inhaled corticosteroids (n = 9) were continued in the same dosage; no other asthma medications were used. Subjects had no relevant allergen exposure, respiratory tract infection, or change in asthma maintenance therapy for at least 4 weeks. Two methacholine challenges, one using each method, were performed in random order.
Tidal-Breathing Method
The 2-min tidal-breathing method was performed as outlined127; Bennett Twin jet nebulizers (Puritan-Bennett Corporation; Carlsbad, CA) were calibrated with 3 mL of saline solution by weighing before and after a 2-min period of nebulization to deliver a mass loss of 0.13 g/min approximating an output of 0.13 mL/min. Aerosols were directed to the subject via a loose-fitting facemask. Subjects wore a nose clip and inhaled each aerosol for 2 min of tidal breathing. Sterile isotonic saline solution was initially inhaled followed by doubling concentrations starting as outlined in previous publications.78 The available concentrations ran from 0.03 to 16 mg/mL. Full spirograms were initially done in triplicate. After the completion of each inhalation, single technically acceptable truncated spirograms were performed to obtain an FEV1 at both 30 s and 90 s. The dose step-up timing was kept constant with a 5-min time interval between the commencement of one concentration and the commencement of the next. The percentage fall in FEV1 was calculated from the lowest post-saline solution FEV1 to the lowest post-methacholine FEV1.279 The test was continued until the FEV1 had fallen by 20%, and the PC20 was calculated.10
Dosimeter Method
The dosimeter method13 was performed using DeVilbiss 646 nebulizers (Sunrise Medical HHG; Somerset, PA) and a KoKo dosimeter (Pulmonary Data Services; Doylestown, PA). The DeVilbiss 646 nebulizers were calibrated to produce a mass loss of 9 mg per actuation, approximately equivalent to 9 µL per breath. Triplicate calibrations were done with 3 mL in the nebulizer by having the calibrator take 10 slow-breath activations from functional residual capacity to total lung capacity (TLC) followed by a 5-s breathhold and exhalation to the room. The five-breath dosimeter methacholine challenge was done using the identical methacholine solutions (0.03 to 16 mg/mL), starting concentration, FEV1 timing, dose step-up timing, PC20 calculation, etc., as the tidal-breathing method. Only the inhalation method was different. The method of inhalation was five slow inspiratory capacity (functional residual capacity to TLC) inhalations followed by a 5-s breathhold at TLC with exhalation to the room following each inhalation.
Analysis
The primary end point, the PC20, was log transformed and analyzed by paired t test using a computerized statistical program.11
| Results |
|---|
|
|
|---|
65% and a tidal-breathing PC20 < 16 mg/mL completed the investigation without adverse events. A forty-first subject failed to return for the second methacholine challenge and was not included in the analysis. Demographics of the 40 subjects who completed both challenges are given in Table 1
.
|
|
Two of the three subjects with PC20 values extrapolated to > 32 mg/mL returned to the laboratory for repeat dosimeter PC20 determinations using sub-TLC inhalations and breathhold. These two subjects both had measurable dosimeter PC20 values with the sub-TLC inhalation method (12.0 mg/mL and 4.2 mg/mL).
| Discussion |
|---|
|
|
|---|
The dose of aerosol delivered to subjects would be the most obvious and likely most important difference between the two methods. The tidal-breathing method produces an aerosol of 0.13 mL/min for 2 min, giving a total output of 0.26 mL or 260 µL. When this is multiplied by the duty cycle (total duration of respiratory cycle/total breathing cycle time, approximately 0.35), the subject will be exposed to approximately 90 µL at each concentration. This compares to 45 µL (five breaths x 9 µL per breath) at each concentration for the dosimeter method. The approximate double dose administered by the tidal-breathing method would account for the PC20 being approximately one half that of the dosimeter method.
The deposition and retention of aerosol are likely different between methods. It was empirically assumed1 that the slow inspiratory capacity breath and breathhold might result in a superior dose and aerosol retention, which might explain the apparent PC20 equivalence in the earlier histamine provocative concentration comparison between two methods.4 In that study,4 the two methods produced equivalent lung deposition of radiolabeled aerosol; however, the method of dosimeter calibration (see below) was not specified. The mean data suggest that greater aerosol retention is not a factor in our study. However, subjects with moderate-to-marked AHR showed less than the expected 2:1 ratio in provocative concentration values, suggesting greater dosimeter aerosol dose/deposition may have played a role in this group of subjects.
A third consideration in the differences of the method is the effect of maximal inspiration on the measurement of airway responsiveness. Inhalations to TLC are recognized to be bronchodilator and bronchoprotector, particularly in subjects with airway responsiveness in the normal, borderline, or mild range.12 This is important enough so that delaying the time to the first spirogram (ie, until the first inhalation to TLC) following methacholine inhalation to 3 min as opposed to 30 s results in a significantly lower PC20 values across all ranges of airway responsiveness.13 We kept the timing and the number of spirograms constant so this was not a factor in any difference between the two methods. However, the dosimeter method involves five inhalations to TLC with 5-s breathholds. Consequently, the subjects spend a total of 25 to 30 s breathholding at TLC in the 1.0 to 1.5 min before the first spirogram. The bronchodilator/bronchoprotective effect of this maneuver is the likely explanation for the greater discrepancy between the two methods seen in subjects with mild AHR. It also would explain the three subjects with mild-to-borderline AHR on the tidal-breathing method whose PC20 values were unmeasurable with the dosimeter method. Indeed, this was verified in two of these subjects by repeating the dosimeter PC20 with sub-TLC inhalations and obtaining measurable PC20 values. Further investigation into this observation is warranted.
A fourth concern regarding comparative studies looking at the two methods is the mechanism of dosimeter nebulizer calibration. We have demonstrated large variations in apparent measured nebulizer output with dosimeter-nebulizer systems based on how the calibration is performed. As noted above, we routinely calibrate our dosimeter nebulizer systems by weighing the nebulizer before and after breath activation followed by exhalation into the room. When the nebulizers are operated at these running parameters and the nebulizer recalibrated by having the subject breath activate the nebulizer and exhale back into the nebulizer, the measured output (mass loss) is less by about a factor of one third, likely because of condensation from the exhaled breath within the nebulizer. The result is an underestimate of the mass loss.14 When the nebulizer is activated by manual activation (activation via a switch with no subject inhaling), the measured output, when operated at these parameters, is less by a factor of two thirds, almost certainly because the aerosol does not completely clear the dead space of the nebulizer and remains within. Conversely, if the nebulizer dosimeter operating parameters are adjusted to obtain a measured output of 9 µL per breath using the latter two methods, the operating characteristics have to be increased such that the true output is greater. It is possible that differences in nebulizer calibration in different studies could explain in whole or in part different comparative results.
The two previous methods comparison investigations have suggested similar PC20 values by the two tests. Ryan et al4 examined histamine PC20 using 2-min tidal breathing method with a Wright nebulizer at a slightly higher output than usual (0.147 mL/min) and a very small particle size: aerodynamic mass median diameter of (AMMD) 0.87 µm. This was compared to a dosimeter method using a nebulizer (model 646; DeVilbiss; Minneapolis, MN) calibrated (means unspecified) to an output of 9 µL per breath and operated by a Rosenthal-French dosimeter. There were 10 subjects in this study. Geometric mean PC20 was 1.8 mg/mL with tidal breathing and 2.2 mg/mL with the dosimeter method. This study may not be comparable to ours for at least two reasons. The first is the method of dosimeter calibration was not specified, and this could have influenced the study. The second is that the very small Wright nebulizer particle size may be the reason for reduced effect produced by some (particularly Canadian-made) Wright nebulizers15; the small particle size aerosol may behave in part like a gas with a greater proportion of aerosol being exhaled. The reduced response produced by the Canadian Wright nebulizer is the major reason that we switched to the Bennett Twin jet nebulizer, which has a more appropriate particle size with the AMMD between 3 µm and 4 µm.16 The other methods comparison study5 compared the tidal-breathing method using doubling-dose steps of methacholine and a Canadian Wright nebulizer, and the dosimeter method using quadrupling-dose steps (a recommended ATS option) and the DeVilbiss 646 nebulizer. Eleven of the 12 subjects were evaluable with a geometric mean PC20 of 4.7 mg/mL for tidal breathing and 3.9 mg/mL for dosimeter. The different dosages make comparison difficult; however, since there is a significant cumulative effect of methacholine when administered at 5-min intervals,13 the cumulative effect should be smaller with quadrupling doses. If so, this should contribute to the dosimeter PC20 being higher (rather than lower) than with doubling doses; therefore, this is not a plausible explanation for why their study differs from ours. Their tidal-breathing method used a Canadian Wright nebulizer, some of which have been previously demonstrated to produce a markedly lower response than the English Wright nebulizer15 probably because of the very small particle size (AMMD < 1 µm). Thus, some Canadian Wright nebulizers may underestimate AHR. The particle size of the nebulizer used in the study by Wubbel et al5 is not specified. Likewise, the means of calibration of the dosimeter nebulizer system discussed above (DeVilbiss) was also not specified. Several other studies17181920 cannot be compared to ours because of methodologic differences or lack of documentation of nebulizer output.
These results indicate that when the tests are done as outlined by the ATS, different cut points should be used for the different methods. The ATS has suggested 16 mg/mL as the cut point between normal and borderline, 4 mg/mL as the cut point between borderline and mild, and 1 mg/mL as the cut point between mild and moderate to marked.1 These are based on the tidal-breathing method.7 Based on the current study, the cut points should be increased to 32 mg/mL, 8 mg/mL, and 2 mg/mL, respectively, for the dosimeter method.
Both methods were well tolerated. Subjects indicated a slight preference (not significant) in favor of the tidal-breathing method, which was perceived as easier; several subjects expressed no preference. From a scientific point of view, it has been believed that there was generally very little to choose between the two methods when properly standardized.1347 However, our observation of several subjects with clinical asthma, mild AHR by the tidal-breathing method, and no measurable airway hyperresponsiveness by the dosimeter method would suggest that the bronchodilator/bronchoprotective effect of the dosimeter method itself may, in fact, reduce the sensitivity of the test and lead to some false-negative test results in subjects at the mild end of the AHR spectrum. This is the area where the majority of positive test results are likely to occur in clinical practice when testing subjects with symptoms and normal spirometry.
| Acknowledgements |
|---|
| Footnotes |
|---|
Dr. Cockcroft is the Ferguson Professor of Respiratory Medicine.
Supported by a grant from Methapharm Inc.
Supported by the Lung Association of Saskatchewan.
Received for publication May 14, 2004. Accepted for publication August 6, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. W. Cockcroft Methacholine Challenge Methods Chest, October 1, 2008; 134(4): 678 - 680. [Full Text] [PDF] |
||||
![]() |
L. Prieto, V. Lopez, R. Llusar, R. Rojas, and J. Marin Differences in the Response to Methacholine Between the Tidal Breathing and Dosimeter Methods: Influence of the Dose of Bronchoconstrictor Agent Delivered to the Mouth Chest, October 1, 2008; 134(4): 699 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Prieto, I. Reig, R. Rojas, A. Ferrer, and J. Domenech The effect of challenge method on sensitivity and reactivity to adenosine 5'-monophosphate in subjects with suspected asthma. Chest, November 1, 2006; 130(5): 1448 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Allen, B. E. Davis, T. S. Hurst, and D. W. Cockcroft Difference Between Dosimeter and Tidal Breathing Methacholine Challenge: Contributions of Dose and Deep Inspiration Bronchoprotection Chest, December 1, 2005; 128(6): 4018 - 4023. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |